ArticleApoptosis : an international journal on programmed cell death2026
DKK1 expression associates with tertiary lymphoid structure maturity in non-small cell lung cancer.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tertiary lymphoid structures (TLS) are organized lymphoid aggregates that form outside lymph nodes within the tumor microenvironment. They are linked to better prognosis and stronger antitumor immune responses. However, the key molecular factors that control TLS maturation in non-small cell lung cancer (NSCLC) are still not clear, and their prognostic value is not fully defined. We analyzed TLS-related genes to identify markers linked to prognosis. We used consensus clustering to define molecular subtypes with different survival outcomes. We then built a TLS risk score signature (TLSRS) using LASSO-Cox regression and tested it in independent meta-GEO cohorts. We also examined the association between DKK1 expression and TLS maturation by multiplex immunofluorescence in a clinical cohort. TLSRS separated patients into high- and low-risk groups in the training cohort (n = 503, P < 0.0001) and in the validation cohorts (n = 681, P < 0.0001). The time-dependent AUC values were 0.762, 0.710, and 0.708 at 1, 3, and 5 years. Multivariable analysis showed that TLSRS was an independent prognostic factor in all cohorts. Patients with low TLSRS showed higher immune cell infiltration and higher CCL19 expression, and they also showed stronger immune-related activity across cohorts. In an independent in-house cohort (n = 119), higher DKK1 expression was linked to worse overall survival. DKK1 expression was negatively correlated with the TLS maturity ratio, but it was not correlated with the number of TLS. We developed a prognostic TLSRS that captures key features of the immune microenvironment in NSCLC. We also found that DKK1 may act as a negative regulator of TLS maturation. These results help explain TLS biology and suggest that DKK1 could be a therapeutic target to improve antitumor immunity in NSCLC.
Indexed as
Identifiers
41904774What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.